Flora Growth Completes First Cannabis Extraction Through New Facility
In December of 2021, Flora’s laboratory quality assurance and regulatory team completed the installation and testing of all extraction equipment. The team successfully extracted the first batch of High-THC crude oil, where the product was submitted to the Colombian Government to obtain Flora’s 2022 quota for THC derivatives. At this time, the team is continuing commercial CBD extraction.
With this major milestone complete, the company has initiated pre-audit work for the completion of the EU-GMP certification. Upon receipt of EU-GMP certification, and when paired with Flora Growth’s recent Good Agricultural and Collection Practices (GACP) certification, Flora will be positioned to target international medical cannabis markets. Flora intends on leveraging its cost advantage – with the company’s low-cost, outdoor-cultivated cannabis grown as inexpensively as 6 cents per gram – to penetrate international medical cannabis markets with its low-cost dried flower and derivatives.
Flora Growth’s post-harvest and extraction facility stands at 10,500 square feet at Flora’s cultivation site in Bucaramanga, Colombia, bringing total extraction capacity to over 15,000 liters of distillate annually. The new facility is fully automated and features cryo-ethanol extraction that yields economical and high-quality cannabinoid derivatives at high-throughput. The facility expedites Flora’s ability to produce dried and packaged flower, derivatives, distillate, and finished goods entirely in-house.
“Being fully integrated, with internal processing, paired with our expanding distribution channels, was a strategic decision and one that we believe will have long-term benefit as the cannabis derivatives market further stabilizes and expands,” said Jason Warnock, chief revenue officer of Flora Growth. “This new facility will also help to increase the range of our product offerings, so that our team can not only produce high-quality cannabis flower, but also produce derivatives and active pharmaceutical ingredients (or APIs) for international medical markets.”